The group’s principal activity is to develop potential targeted biologic treatment including cytotoxic drugs to cancer cells, therapeutic effect of vitamin B12 depletion by receptor modulators and monoclonal antibodies to block the vitamin B12 uptake by cancer. The group operates from the United States and Canada.